Celgene
Celgene ‘stops Mylan entering market’
April 6, 2014Sales and Marketing Celgene, Mylan, Revlimid, myeloma
Generic manufacturer Mylan is suing Celgene in a spat over allowing copycat versions of existing cancer drugs – Revlimid and …
New director named at Celgene
March 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, moore
Biopharma firm Celgene has appointed Rob Moore as its new Inflammation and Immunology business unit director. Moore has worked in …
Celgene ‘downplayed’ Thalomid, Revlimid risks
February 7, 2014Medical Communications, Sales and Marketing Celgene, Revlimid, Thalidomide, thalomid
A former sales representative for US pharma firm Celgene is accusing her old company of promoting two of its key …
Cancer treatment Abraxane gets EU nod
January 9, 2014Sales and Marketing Abraxane, Cancer, Celgene, EU, pancreatic
Celgene’s cancer drug Abraxane has been approved by European regulators to treat patients with metastatic adenocarcinoma of the pancreas, or …
Celgene signs $177 million OncoMed deal
December 4, 2013Research and Development, Sales and Marketing Cancer, Celgene, OncoMed, stem cell
Celgene Corporation is paying OncoMed Pharmaceuticals $177.25 million to get access to its pipeline as part of a deal to …
Celgene hires new medical director
November 12, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, kilcoyne
Biopharma firm Celgene has announced the appointment of Dr Adrian Kilcoyne as its new medical director. He will take up …
Celgene’s multiple myeloma pill launched in UK
August 15, 2013Sales and Marketing Celgene, Velcade, low, myeloma
Celgene’s new oral blood cancer drug pomalidomide has been launched in the UK and Ireland as a third line treatment …
NICE no for Celgene’s Revlimid
July 11, 2013Sales and Marketing Celgene, NICE, Revlimid
NICE has issued new draft guidance not recommending Celgene’s bone marrow disorder drug Revlimid over uncertainties of its efficacy. Revlimid …
Celgene predicts trio of blockbusters
June 5, 2013Sales and Marketing Celgene, Pomalidomide, Revlamid, Velcade
Europe’s medicines committee the CHMP has just adopted a positive opinion for Celgene’s new multiple myeloma treatment Pomalidomide Celgene (pomalidomide). …
Celgene appoints new Haematology head
April 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, browne
Celgene has announced the appointment of Karen Browne as business unit director of Haematology, Celgene UK and Ireland. Over the …
Big pharma appointments to PhRMA Board
April 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Pharma, Celgene, Merck, Pfizer, PhRMA
Chairman and chief executive of Celgene Robert Hugin has been elected chairman of the Pharmaceutical Research and Manufacturers of America …
Celgene appoints new Human Resources director
January 2, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene
Celgene has announced the appointment of Sarah Bater as director of Human Resources, Celgene UK and Ireland. Bater brings a wealth …
Revlimid patient scheme ‘working’
December 14, 2012Sales and Marketing Celgene, Revlimid
Celgene has issued figures which it says demonstrate the clinical value of the NICE-agreed patient access scheme for its cancer …
New director of market access at Celgene UK and Ireland
June 18, 2012Business Services, Medical Communications, Sales and Marketing Celgene, Nicola Redfern, oncology
Celgene has announced the appointment of Nicola Redfern as director of market access, Celgene UK and Ireland. Redfern brings a …
Celgene appoints Thomas Moriarty as general counsel
May 9, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Moriarty
Celgene has appointed Thomas Moriarty as its new general counsel and corporate secretary. In this position, he will be responsible …
Latest content
FibroFind appoints Lee Borthwick as CEO
